Two Sigma Securities’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Two Sigma Securities’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,608	Closed	-$12K	–	2630
2019 Q2	$12K	Buy	1,608 +58	+4%	+$425	﹤0.01%	1983
2019 Q1	$12K	Buy	1,550 +416	+37%	+$3.91K	﹤0.01%	1721
2018 Q4	$9K	Sell	1,134 -76	-6%	-$912	﹤0.01%	2028
2018 Q3	$19K	Buy	+1,210	New	+$14.6K	﹤0.01%	2454
2017 Q4	–	Sell	-4,633	Closed	-$72K	–	2117
2017 Q3	$72K	Buy	4,633 +3,095	+201%	+$36.5K	0.01%	705
2017 Q2	$14K	Buy	1,538 +343	+29%	+$6.72K	﹤0.01%	800
2017 Q1	$31K	Buy	+1,195	New	+$42.8K	0.01%	828
2016 Q1	–	Sell	-126	Closed	-$6K	–	438
2015 Q4	$6K	Buy	+126	New	+$14K	0.01%	241

Other funds holding IDXG

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Two Sigma Securities's IDXG Position: Q3 2019 in Review

Two Sigma Securities sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2019, closing a stake of 1,608 shares — an estimated $12K sold.

Two Sigma Securities first reported a position in IDXG in Q4 2015 and held it in 8 quarters. The position peaked at $72K in Q3 2017. 17 funds tracked by Wall St. Rank hold IDXG as of Q3 2019.

Two Sigma Securities reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Two Sigma Securities sold 1,608 Interpace Biosciences, Inc. Common Stock shares in Q3 2019, an estimated $12K.
Two Sigma Securities first reported a position in Interpace Biosciences, Inc. Common Stock in Q4 2015 and held it in 8 quarters.
Two Sigma Securities's Interpace Biosciences, Inc. Common Stock position peaked at $72K in Q3 2017.
17 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2019.

Based on Two Sigma Securities's 13F filing for Q3 2019, filed 14 Nov 2019.